Liang Ma

Liang Ma


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2024 in Pharmacological Research
Verified
Journal Article
Open access
WWWenzhao Wang
Wenzhao Wang
CLChang Liu
Chang Liu
DHDong He
Dong He
GSGuidong Shi
Guidong Shi
PSPing Song
Ping Song
LMLiang Ma
Liang Ma
Spinal cord injury (SCI) is a complex problem in modern medicine. Fibroblast activation and fibroscarring after SCI impede nerve recovery. Non-coding RNA plays an important role in the progression of many diseases, but the study of its role in the progression of spinal fibrosis is still emerging. Here, we investigated the function of circular RNAs, specifically antisense to the cerebellar degeneration-related protein 1 (CDR1as), in spinal fibrosis and characterized its molecular mechanism and pathophysiology. The presence of CDR1as in the spinal cord was verified by sequencing and RNA expression assays. The effects of inhibition of CDR1as on scar formation, inflammation and nerve regeneration after spinal cord injury were investigated in vivo and in vitro. Further, gene expression of miR-7a-5p and protein expression of transforming Growth Factor Beta Receptor II (TGF-βR2) were measured to evaluate their predicted interactions with CDR1as. The regulatory effects and activation pathways were subsequently verified by miR-7a-5p inhibitor and siCDR1as. These results indicate that CDR1as/miR-7a-5p/TGF-βR2 interactions may exert scars and nerves functions and suggest potential therapeutic targets for treating spinal fibrotic diseases.

1 October 2022 in Annals of Palliative Medicine
Verified
Journal Article
Open access
PDF file
YSYanlin Su
Yanlin Su
WWWenzhao Wang
Wenzhao Wang
FLFei Liu
Fei Liu
YCYuli Cai
Yuli Cai
NLNianhu Li
Nianhu Li
LMLiang Ma
Liang Ma
Background: Postmenopausal women are one of the most vulnerable groups to osteoporosis. Romosozumab is a newly monoclonal drug that inhibits the activity of sclerostin. Since it has been on the market for only 3 years, there is a lack of systematic analysis on postmenopausal women and the efficacy is not clear. In this study, we compared randomized controlled trials to assess the effects of blosozumab versus placebo in perimenopausal and postmenopausal women. Methods: This meta-analysis has been registered in the PROSPERO registry (number CRD42020145839). The PubMed, Cochrane Library, ClinicalKey, and Embase databases were searched from inception date to July 01, 2021. We used the keywords “osteoporosis”, “decreased bone mass”, and “blosozumab” to retrieve studies on the relationship between blosozumab and osteoporosis in each database. The inclusion criteria were: (I) randomized controlled trials (RCTs) comparing the treatment of osteoporosis with blosozumab and a placebo or without treatment, (II) studies on postmenopausal women aged over 50 years, and (III) studies providing bone mineral density data. The quality of all randomized controlled trials included in this study was independently assessed by two researchers according to the Cochrane risk manual and was divided into high, medium and low quality. The main results analyzed were bone mineral density (BMD) and T-score. Our results mainly include BMD and procollagen type I N-terminal propeptide (P1NP), C-terminal telopeptide of type I collagen (CTX), bone-specific alkaline phosphatase (BSAP), and osteocalcin (OC). Results: Three RCTs with 105 patients were selected from 157 retrieved articles. Due to high heterogeneity [BMD: Tau2=2.79; Chi2=11.70, degrees of freedom (df) =1 (P=0.0006); I2=91%], we could not perform statistical analysis of BMD. The results of BMD were then evaluated systematically. Three RCT studies were included in the evaluation. Compared with that of the placebo, blosozumab increased levels of the BMD biomarker osteocalcin [mean deviation (MD) 12.55; 95% confidence interval (CI), 8.18, 16.91; P<0.00001]. None of the 3 RCTs presented a risk of bias during the meta-analysis. Conclusions: The results suggested that blosozumab could be used as a target drug to improve BMD in postmenopausal women. This will provide a reference for the clinical treatment of postmenopausal women with osteoporosis.

28 May 2025 in Journal of Translational Genetics and Genomics
Verified
Journal Article
Open access
PDF file
CWChuanxin Wang
Chuanxin Wang
WWWenfei Wu
Wenfei Wu
BYBingyang Yan
Bingyang Yan
DLDi Luo
Di Luo
YGYanbo Guo
Yanbo Guo
LMLiang Ma
Liang Ma
Aim: Osteoporosis (OP) is the most common of the musculoskeletal disorders, with decreased bone mineral density (BMD) being the main manifestation and exacerbating fracture susceptibility. OP was once thought to be an inevitable consequence of aging. We conducted a bi-directional Mendelian randomization (MR) for epigenetic age acceleration (EAA) and osteoporosis to accurately assess the interaction between aging and osteoporosis. Methods: This study collected data from genome-wide association studies of EAA and OP and assessed significant genetic variables. Bi-directional MR analyses were performed using random-effects inverse-variance weighting as the primary method, and the interaction of epigenetic age acceleration with OP was assessed using other MRI methods and multiple sensitivity analyses. Results: Inverse-variance weighted (IVW) results suggest that GrimAge acceleration accelerates bone loss in total body bone mineral density [odds ratio (OR) = 1.035, 95% confidence interval (95%CI) = (1.003, 1.069), P = 0.033]. The effect of BMD on EAA was investigated, and a causal relationship was found between forearm bone mineral density and GrimAge acceleration [OR = 0.682, (95%CI) = (0.508, 0.916), P = 0.011]. There was a causal relationship between femoral neck bone mineral density and PhenoAge acceleration [OR = 1.452, (95%CI) = (1.007, 2.096), P = 0.046]. Conclusions: Epigenetic age acceleration was bi-directionally causally associated with osteoporosis. GrimAge acceleration increased the risk of decreased total body bone mineral density. Forearm bone mineral density accelerated GrimAge and femoral neck bone mineral density accelerated PhenoAge acceleration.